Patricia Inacio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inacio

Phase 2b trial of AD04 in mild Alzheimer’s enrolls first patient

A proof-of-concept Phase 2b clinical trial evaluating the safety and efficacy of Advantage Therapeutics’ investigational immunotherapy AD04 in people with mild Alzheimer’s disease has enrolled its first patient. The placebo-controlled study is being conducted in Austria, France, Poland, Bulgaria, and Slovakia, and is expected to open clinical sites in Germany and…

Data: ALPHA-1062 a Bioequivalent to Approved Therapy Razadyne

Alpha Cognition’s candidate oral tablet ALPHA-1062, for mild to moderate Alzheimer’s disease, showed efficacy as a bioequivalent substitute for the approved therapy Razadyne (galantamine), according to top-line data from a trial with healthy volunteers. Per this new data, as a delayed-release tablet, ALPHA-1062 showed…

ALPHA-1062 May Be Substitute for Razadyne: Bioequivalence Study

ALPHA-1062, Alpha Cognition’s investigational oral tablet for mild to moderate Alzheimer’s disease, may be a bioequivalent substitute for the approved therapy Razadyne, according to a pivotal trial with healthy volunteers. The pro-drug therapy — meaning that the medication is metabolized in the body, after administration — showed positive…